Monoclonal antibodies: Pharmacological relevance

被引:4
作者
Kaur, Jasleen [1 ]
Badyal, O. K. [1 ]
Khosla, P. P. [1 ]
机构
[1] Christian Med Coll & Hosp, Dept Pharmacol, Ludhiana, Punjab, India
关键词
antibodies; biological response modifiers; cancer chemotherapy; immunosuppressant; immunotherapeutics;
D O I
10.4103/0253-7613.30755
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Monoclonal antibodies (MAbs), a new class of biological agents, are used these days in therapeutics and diagnosis. MAbs also labeled as 'magic bullets', are highly specific antibodies produced by a clone of single hybrid cells formed in the laboratory by fusion of B cell with the tumor cell. The hybridoma formed yields higher amount of MAbs. MAbs can be produced in vitro and in vivo. Animals are utilized to produce MAbs, but these antibodies are associated with immunogenic and ethical problems. Of late, recombinant DNA technology, genetic engineering,phage display and transgenic animals are used to produce humanized MAbs or pure human MAbs, which have fewer adverse effects. MAbs alone or conjugated with drugs, toxins, or radioactive atoms are used for treatment of cancer, autoimmune disorders, graft rejections, infectious diseases, asthma, and various cardiovascular disorders. New MAbs are being developed which are more specific and less toxic.
引用
收藏
页码:5 / 14
页数:10
相关论文
共 79 条
  • [1] [Anonymous], COCHRANE DATABASE SY
  • [2] Antoni C, 2002, ARTHRITIS RHEUM-US, V46, pS381
  • [3] Antoni CE, 2003, ANN RHEUM DIS, V62, P90
  • [4] BAKER DD, 2001, INDIAN J MED SCI, V55, P651
  • [5] Bitton RJ, 2002, ONCOL REP, V9, P267
  • [6] Genetically engineered monoclonal antibodies for direct anti-neoplastic treatment and cancer cell specific delivery of chemotherapeutic agents
    Bodey, B
    Bodey, B
    Siegel, SE
    Kaiser, HE
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2000, 6 (03) : 261 - 276
  • [7] PRACTICAL CONSIDERATIONS IN THE PRODUCTION, PURIFICATION, AND FORMULATION OF MONOCLONAL-ANTIBODIES FOR IMMUNOSCINTIGRAPHY AND IMMUNOTHERAPY
    BOGARD, WC
    DEAN, RT
    DEO, Y
    FUCHS, R
    MATTIS, JA
    MCLEAN, AA
    BERGER, HJ
    [J]. SEMINARS IN NUCLEAR MEDICINE, 1989, 19 (03) : 202 - 220
  • [8] A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis
    Boumpas, DT
    Furie, R
    Manzi, S
    Illei, GG
    Wallace, DJ
    Balow, JE
    Vaishnaw, A
    [J]. ARTHRITIS AND RHEUMATISM, 2003, 48 (03): : 719 - 727
  • [9] Treatment of active ankylosing spondylitis with infliximab:: a randomised controlled multicentre trial
    Braun, J
    Brandt, J
    Listing, J
    Zink, A
    Alten, R
    Golder, W
    Gromica-Ihle, E
    Kellner, H
    Krause, A
    Schneider, M
    Sörensen, H
    Zeidler, H
    Thriene, W
    Sieper, J
    [J]. LANCET, 2002, 359 (9313) : 1187 - 1193
  • [10] Therapeutic monoclonal antibodies
    Breedveld, FC
    [J]. LANCET, 2000, 355 (9205) : 735 - 740